Replimune Group, Inc. nears a pivotal FDA AdCom for RP1 ahead of an Aug 2, 2026 decision. Click for this REPLY stock update ...
Many Australians living with neurological disorders, such as motor neuron disease and multiple sclerosis, experience speech difficulties and may lose their ability to speak. There are limited ...
The idea that the gap junction family of proteins, connexins, are tumour suppressors has been widely supported through numerous cancer models. However, the paradigm that connexins and enhanced gap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results